Listed by the USPTO as ARNOLD, ERNST V
Tech Center 1600 • Art Units: 1600 1613 1614 1616 1617 1626
This examiner grants 48% of resolved cases
ARNOLD, ERNST V is assigned to Tech Center 1600 and Art Unit 1600. The record includes 1399 resolved cases, an allowance rate of 48.2%, and a median of 1165 days to allowance. The large case volume gives the outcome rate substantial historical context. The median indicates that prosecution may continue for a significant period before allowance, making timing a central planning issue.
The interview lift is 12.6%, providing a separate measure for evaluating examiner communication. The listed companies are L'Oréal, Cydex Pharmaceuticals Inc., and Fujifilm Holdings Corporation. The listed firms are Greenberg Traurig, LLP (BOS), Sughrue Mion, PLLC, and ArentFox Schiff LLP - New York. These recurring names may assist counsel researching relevant prosecution activity.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18884577 | LIPID COMPOSITION | Final Rejection | FUJIFILM Corporation |
| 19048816 | GINGEROL COMPOSITIONS AND RELATED METHODS | Final Rejection | ThermoLife International, LLC |
| 18205399 | Hemostatic Foam | Final Rejection | STRYKER EUROPEAN OPERATIONS HOLDINGS LLC |
| 18674730 | PREPARATION OF PHARMACEUTICAL COMPOSITIONS USING SUPERCYCLE VAPOR PHASE DEPOSITION OF METAL OXIDES | Non-Final OA | Applied Materials, Inc. |
| 17622585 | TRANSFECTION METHOD | Final Rejection | Takeda Pharmaceutical Company Limited |
| 17831796 | Oral Care Products and Methods | Final Rejection | BASF SE |
| 19016307 | PHARMACEUTICAL COMPOSITIONS FOR IMPROVING INTESTINAL BACTERIAL FLORA AND RELATED TREATMENT METHODS | Final Rejection | Murata Manufacturing Co., Ltd. |
| 18839767 | SPONGES BASED ON COLLAGEN-LIKE PROTEINS | Final Rejection | Evonik Operations GmbH |
| 18842107 | OIL-IN-WATER EMULSION COMPOSITION | Non-Final OA | OTSUKA PHARMACEUTICAL FACTORY, INC. |
| 18993843 | ANTIVIRUS COMPOSITE RESIN COMPOSITION WITH EXCELLENT VIRUS INACTIVATION FUNCTION AND COMPOSITE-RESIN-COATED STEEL SHEET USING SAME | Non-Final OA | POSCO CO., LTD |
| 18679749 | HYBRID NAIL COMPOSITION | Final Rejection | L'ORÉAL |
| 17906514 | CONTINUOUS MELT-COATING OF ACTIVE PHARMACEUTICAL INGREDIENTS USING SURFACTANTS FOR DISSOLUTION ENHANCEMENT | Final Rejection | Rutgers,The State University of New Jersey |
| 18869120 | COSMETIC MATERIAL COMPOSITION AND FIBER TREATMENT COMPOSITION FOR HEAD DECORATION PRODUCTS | Non-Final OA | KAO CORPORATION |
| 18843771 | Materials and Methods for Treating Iron Deficiencies and Iron Chlorosis in Plants | Non-Final OA | Locus Solutions IPCo, LLC |
| 18802979 | STABLE CAPSULES WITH FECAL MICROBIOTA OR A CULTURE OF MICROORGANISMS | Final Rejection | Chr. Hansen A/S |
| 18287604 | Thermally Stable Lipid-Nucleic Acid Molecule Formulations Utilising Metal Organic Framework (MOF) Shells | Non-Final OA | Commonwealth Scientific and Industrial Research Organisation |
| 18631588 | CLEVIDIPINE EMULSION FORMULATIONS CONTAINING ANTIMICROBIAL AGENTS | Final Rejection | CHIESI FARMACEUTICI S.P.A. |
| 17755425 | Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them | Final Rejection | MannKind Corporation |
| 18810352 | LIPID COMPOUND, LIPID NANOPARTICLE COMPRISING SAME AND USE THEREOF | Non-Final OA | TheMedium Therapeutics Co., Ltd |
| 18690921 | COMPOSITIONS OF RAPAMYCIN AND THEIR USE IN THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATION | Final Rejection | PALVELLA THERAPEUTICS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy48.2% of resolved applications examined by Ernst V Arnold were allowed (1,399 resolved cases), compared with 36.5% across Art Unit 1600 over the last five years.
This examiner's interview lift is +12.6 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Ernst V Arnold took 1,165 days on average from filing to allowance.
Ernst V Arnold examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).